Cargando…
Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C
BACKGROUND: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159796/ https://www.ncbi.nlm.nih.gov/pubmed/30288069 http://dx.doi.org/10.2147/CEOR.S171248 |